By Open Chronicle Science Desk
October 1, 2026
An international review involving more than 43,000 women exposed to GLP 1 receptor agonists found no significant association with most major adverse pregnancy outcomes. But researchers warn that major evidence gaps remain, particularly for miscarriage, exposure later in pregnancy, breastfeeding and the long term health of mothers and children.
As millions of women worldwide increasingly use GLP 1 receptor agonists for diabetes and weight management, one question has become progressively more urgent: what happens when these medications intersect with pregnancy?
New international research offers some reassurance, while also highlighting how much remains unknown.
A systematic review and meta analysis of seven studies involving more than 43,000 women exposed to GLP 1 receptor agonists found no significant association between exposure and several major adverse pregnancy outcomes, including preterm birth, stillbirth or neonatal death, caesarean delivery, hypertensive disorders of pregnancy, pre eclampsia and having an infant small for gestational age.
The analysis also found no evidence of increased congenital anomaly risk following exposure followed by discontinuation during the first trimester compared with pregnancies without GLP 1 receptor agonist exposure.
But the researchers stress that these findings should not be interpreted as evidence that GLP 1 therapies have been established as safe throughout pregnancy.
Most available evidence concerns exposure around conception or during early pregnancy. Data for continued treatment during the second and third trimesters remain extremely limited, while evidence surrounding breastfeeding and longer term outcomes for children is also sparse.
The research is being presented at the Annual Meeting of the European Association for the Study of Diabetes in Milan, running from September 28 to October 2, and published in The Lancet Obstetrics, Gynaecology & Women’s Health.
A Rapidly Growing Question in Women’s Health
GLP 1 receptor agonists have transformed the treatment of type 2 diabetes and obesity.
The medications mimic or enhance pathways associated with glucagon like peptide 1, a naturally occurring hormone involved in glucose regulation, insulin secretion and appetite.
Their ability to improve blood sugar control while producing substantial weight loss has led to rapidly increasing use.
That expansion increasingly includes women of reproductive age.
At the same time, diabetes during pregnancy is becoming more common globally.
Pregnancy may be complicated by type 1 diabetes, type 2 diabetes or gestational diabetes mellitus, and metabolic health before conception can have important consequences for both mother and child.
Improving blood glucose levels and, when appropriate, reducing excess weight before conception can therefore form an important part of pregnancy planning for women living with diabetes.
GLP 1 based therapies could potentially contribute to that preparation.
The problem is that their rapid adoption has moved faster than the evidence surrounding reproduction and pregnancy.
More Than 43,000 Exposed Women
To establish what is currently known, researchers conducted a systematic review of the available evidence and included seven studies encompassing more than 43,000 participants exposed to GLP 1 receptor agonists in their meta analysis.
Six of the seven studies examined exposure during the first trimester of pregnancy.
The remaining study considered exposure at any time during the 12 months before pregnancy, a period that could also encompass early pregnancy exposure.
There was another important limitation.
The precise timing of exposure in terms of individual weeks of pregnancy was frequently not well documented.
That makes it considerably more difficult to determine whether particular stages of fetal development carry different risks.
Nevertheless, the combined dataset allowed researchers to examine several important pregnancy outcomes.
No Significant Association With Most Major Outcomes
The meta analysis found no statistically significant association between GLP 1 receptor agonist exposure and a number of adverse pregnancy outcomes.
These included preterm birth, stillbirth or neonatal death, caesarean delivery, pregnancy related hypertensive disorders, pre eclampsia and infants being small for gestational age.
Available evidence, predominantly involving women with type 2 diabetes, also suggested no increase in congenital anomaly risk when GLP 1 receptor agonists were discontinued during the first trimester compared with pregnancies without GLP 1 exposure.
That finding is particularly relevant because some pregnancies occur unexpectedly while a woman is already receiving a GLP 1 therapy.
However, absence of a detected association is not equivalent to proving absence of risk.
The strength of conclusions depends on the quality, size and design of the underlying studies, and some clinically important questions remain supported by very little evidence.
The Complicated Finding on Pregnancy Loss
One result requires particularly careful interpretation.
Early pregnancy loss, defined across the included studies as occurring before approximately 14 to 22 weeks, appeared 31 percent more common among exposed women.
That figure came from two studies involving 41,046 participants.
At first glance, it could suggest an important safety signal.
But there is a major methodological problem.
The study representing approximately 99 percent of the women contributing to this analysis combined spontaneous miscarriage and deliberate termination of pregnancy within the same outcome category.
Researchers therefore could not determine how many pregnancies ended through spontaneous miscarriage and how many were intentionally terminated.
That distinction fundamentally changes how the result can be interpreted.
The observed increase consequently cannot establish that GLP 1 receptor agonists increase miscarriage risk.
Instead, the researchers identify pregnancy loss as one of the areas requiring substantially better evidence.
Why Exposure Timing Matters
Pregnancy is not a single biological state.
Fetal development changes dramatically from conception through birth, and exposure to a medication at one stage may have very different implications from exposure at another.
This makes the timing of GLP 1 receptor agonist exposure particularly important.
The current evidence is concentrated heavily around the first trimester.
Information concerning exposure during the second and third trimesters is extremely limited.
Researchers therefore cannot reliably extrapolate the reassuring findings associated with early exposure across the remainder of pregnancy.
Robust studies examining maternal, fetal and offspring outcomes after later pregnancy exposure remain necessary.
An International Consensus
The research went beyond a conventional systematic review.
The investigators developed what they describe as the first international consensus recommendations concerning GLP 1 receptor agonist use across the reproductive journey in women with diabetes.
The process integrated three major sources of evidence.
Researchers evaluated the systematic review and meta analysis involving more than 43,000 exposed women.
They brought together 42 specialists with international representation.
They also incorporated perspectives from 60 women with lived experience.
The resulting recommendations address GLP 1 receptor agonist use around preconception health, pregnancy and the postpartum period while explicitly acknowledging the limitations of existing evidence.
A Potential Role Before Pregnancy
The consensus panel supported a potential role for GLP 1 receptor agonists in preconception metabolic health optimisation where needed for women with type 2 diabetes.
This reflects the substantial benefits these medications can provide for blood glucose control and weight reduction.
Entering pregnancy with better metabolic health can itself be important.
Poorly controlled diabetes during pregnancy is associated with increased risks for both mother and baby, making effective preparation before conception an important component of diabetes care.
The panel also recognised potential benefits for women with type 1 diabetes and those with a previous history of gestational diabetes.
But here the evidence becomes considerably weaker.
Direct research involving these groups remains limited, meaning potential benefits should not be confused with established clinical evidence.
Millions of Women, Major Unanswered Questions
Professor Claire Meek, from the Leicester Diabetes Research Centre and Leicester NIHR Biomedical Research Centre, emphasised the scale of the issue.
“Millions of women are now using GLP 1 receptor agonists, but there remain important unanswered questions about their impact on fertility, pregnancy, and maternal and child health,” Meek said.
“Women deserve clearer evidence to guide some of the most important healthcare decisions of their lives. As new weight loss medications enter clinical practice at pace, generating robust evidence for women before, during, and after pregnancy has never been more urgent.”
The rapid expansion of the drug class makes that evidence gap increasingly consequential.
GLP 1 based therapies are no longer medications used by a relatively small population.
They are becoming major treatments for chronic metabolic disease and obesity across large sections of the population.
What Happens After Birth?
The evidence becomes even thinner after pregnancy.
Researchers found only limited information concerning postpartum GLP 1 receptor agonist use.
The available evidence included just one small randomised trial involving women who were not breastfeeding and two pharmacokinetic studies examining lactation.
Those studies provide some preliminary information about whether the medications enter breast milk.
Available data suggest that subcutaneously administered GLP 1 receptor agonists may be undetectable or present only at negligible concentrations in breast milk.
But that does not establish clinical safety for breastfeeding infants.
The number of studied women remains small, and researchers lack sufficient information about potential effects on infants.
Questions may also differ between injectable and oral formulations.
The researchers specifically highlight uncertainty surrounding oral therapies containing absorption enhancers, which could behave differently.
The Long Term Questions Are Even Bigger
Immediate pregnancy outcomes represent only one part of the scientific problem.
Researchers also want to know whether exposure could have consequences appearing years later.
Studies will eventually need to examine the longer term metabolic and developmental health of children whose mothers used these medications before or during pregnancy.
Maternal outcomes also require continued investigation.
For example, researchers need to understand whether using GLP 1 therapies before conception produces lasting metabolic benefits after pregnancy and whether restarting treatment after birth influences maternal health.
Fertility itself represents another major area requiring further research.
The interactions between weight loss, metabolic improvement, reproductive hormones and fertility are complex.
As increasing numbers of women use GLP 1 based medications, prospective research capable of following them throughout the entire reproductive journey will become increasingly valuable.
Different GLP 1 Drugs May Not Be Identical
Another limitation is the tendency to discuss GLP 1 receptor agonists as a single category.
Individual medications differ.
They can have different molecular structures, durations of action, doses, administration routes and pharmacological characteristics.
Researchers therefore argue that future studies should provide separate information for different GLP 1 based therapies rather than treating all drugs as interchangeable.
The duration of exposure also needs to be recorded much more precisely.
Knowing simply that someone was exposed during the first trimester provides less information than knowing exactly when treatment stopped and how long the medication remained in the body.
Route of administration is another potentially important variable.
These distinctions will become increasingly relevant as new generations of metabolic medicines enter clinical practice.
Reassuring Evidence, But Not a Declaration of Safety
The central finding requires careful interpretation.
The current evidence does not show significant associations between GLP 1 receptor agonist exposure and most of the major adverse pregnancy outcomes examined.
That is reassuring, particularly for women who discover they are pregnant after having recently used one of these medications.
But the evidence does not establish that GLP 1 receptor agonists can be considered broadly safe for routine use throughout pregnancy.
The researchers themselves emphasise the remaining uncertainties.
Evidence surrounding miscarriage remains difficult to interpret.
Data for exposure beyond the first trimester are extremely sparse.
Information concerning breastfeeding is limited.
Direct evidence for women with type 1 diabetes and previous gestational diabetes remains insufficient.
Long term outcomes for mothers and children are largely unknown.
These limitations matter when translating population research into individual medical decisions.
Women who are pregnant, planning pregnancy or breastfeeding should therefore discuss GLP 1 therapy with their healthcare professionals rather than starting, stopping or modifying treatment on the basis of population findings alone.
Research Must Catch Up With Clinical Reality
There is a broader lesson behind the study.
Medical practice can change faster than reproductive health evidence develops.
Women of reproductive age have historically been underrepresented in some areas of clinical research, while pregnant women are commonly excluded from drug trials because of legitimate ethical and safety concerns.
The consequence is a recurring evidence problem.
When widely used medicines eventually intersect with pregnancy, clinicians and patients may have to make important decisions with incomplete information.
GLP 1 receptor agonists illustrate the challenge particularly clearly because their adoption has been extraordinarily rapid.
Tens of thousands of real world exposures can occur before prospective pregnancy studies are available.
Systematic reviews and observational data can help fill that gap, but they cannot answer every question.
Building the Evidence Women Need
The international panel concludes that substantially larger prospective studies are urgently needed.
Future research should track women before conception, throughout pregnancy and after birth.
It should distinguish between individual GLP 1 therapies.
Researchers need precise information about dose, duration and timing of exposure.
Pregnancy losses should distinguish spontaneous miscarriage from elective termination.
Breastfeeding studies need to examine not only drug concentrations in milk but actual clinical outcomes in infants.
Children will need longer term follow up to identify possible metabolic or developmental consequences that cannot be detected at birth.
And researchers need stronger evidence involving women with type 1 diabetes, type 2 diabetes and previous gestational diabetes as distinct populations.
The new analysis provides an important starting point.
For women inadvertently exposed to GLP 1 receptor agonists around conception or during early pregnancy, the absence of clear associations with most major adverse outcomes offers meaningful reassurance.
But it also exposes the boundaries of present knowledge.
GLP 1 medicines have transformed diabetes and weight management with remarkable speed.
Understanding their place across fertility, pregnancy and breastfeeding will require reproductive health research to move just as quickly.
Story Source
Materials provided in connection with research presented at the Annual Meeting of the European Association for the Study of Diabetes, EASD, Milan, Italy, September 28 to October 2, 2026.
The research is reported as published in The Lancet Obstetrics, Gynaecology & Women’s Health.
Note: Content may be edited for style and length.
Editorial Note
This article reports population level research and international expert consensus. It does not establish that GLP 1 receptor agonists are safe for routine use throughout pregnancy and should not be interpreted as individual medical advice. Decisions concerning GLP 1 treatment before conception, during pregnancy or while breastfeeding should be discussed with an appropriate healthcare professional.